dc.creatorRamírez, Gonzalo
dc.creatorBriceño, Jimmy
dc.creatorRojas, Armando
dc.date2017-11-22T21:03:17Z
dc.date2017-11-22T21:03:17Z
dc.date2012
dc.date.accessioned2019-11-20T15:10:05Z
dc.date.available2019-11-20T15:10:05Z
dc.identifierhttp://repositorio.ucm.cl:8080/handle/ucm/1333
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3033160
dc.descriptionPortal hypertension is a hemodynamic abnormality that involves a high risk of disability as well as a reduced life expectancy in patients with cirrhosis. Progress in the knowledge of pathophysiology of portal hypertension has opened a new perspective for different pharmacological approaches. In this context, the pleiotropic actions of statins on endothelial cell function have emerged as new options to reduce portal pressure levels by targeting multiple molecular pathways involved in hepatic vascular homeostasis. We highlight how statins may target some molecular pathways involved in the pathophysiology of portal hypertension and how these drugs may correct impaired hepatic vascular tone.
dc.languageen
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.sourceCurrent Vascular Pharmacology, 10(6), 767-772
dc.subjectLiver cirrhosis
dc.subjectHepatic stellate cell
dc.subjectIntrahepatic vascular resistance
dc.subjectPortal hypertension
dc.subjectVascular endothelium
dc.titleStatins and portal hypertension: A new pharmacological challenge
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución